Anyone researching hyperbaric oxygen therapy hits the number "40 sessions" almost immediately. It is the default protocol for diabetic foot ulcers, late-effect radiation tissue injury, and most off-label uses too. This guide explains where 40 came from and why it stuck. See the late radiation tissue injury evidence atlas for the full study-by-study evidence breakdown.
The short version: the diabetic-foot and radiation-osteonecrosis trials that established Medicare coverage in the 1980s and 1990s ran 30 to 40 sessions. Subsequent protocols adopted the same window. The number is not magical; it reflects how long it takes hyperoxia to drive measurable wound-bed change.
We will cover the original trials, the biology, the variants (20, 60, 80 sessions), and how to read a clinic's recommendation.
Where 40 sessions came from
The 40-session protocol traces to two research lines in the 1980s. First, Marx & Johnson's work on radiation osteonecrosis at the University of Miami in the late 1970s and 1980s. Second, the diabetic foot ulcer trials from European centers in the 1990s.
Robert Marx, an oral surgeon, used HBOT before and after dental extractions in patients who had received head and neck radiation. His "30-pre, 10-post" protocol totaled 40 sessions per procedure. Outcomes for previously refractory radionecrosis improved dramatically.
The Marx protocol became the de facto standard for radiation tissue injury. The number 40 came from clinical observation, not from a dose-response study. Subsequent trials replicated the schedule rather than testing variations.
Faglia and colleagues in Italy ran a randomized trial of HBOT for diabetic foot ulcers, published in Diabetes Care 1996. The protocol was 38 sessions at 2.2 to 2.4 ATA, 5 days per week. Wound-bed transcutaneous oxygen rose significantly; amputation rates dropped.
The Faglia trial became the evidence base for Medicare coverage of diabetic foot ulcers. CMS cited the trial when it issued LCD L33718 authorizing HBOT for Wagner grade 3+ ulcers that have failed 30 days of standard care.
The biology behind 4 to 8 weeks
HBOT works on a slow clock. The key tissue effects take weeks to show up, which is why protocols run long.
Within a single session at 2.4 ATA, arterial PO2 rises from ~100 mmHg to ~1500 mmHg (Tibbles & Edelsberg 1996). That hyperoxia drives several downstream effects.
Short-term: white blood cells kill bacteria faster, tissue swelling drops, and carbon monoxide clears. These effects justify single-session protocols for CO poisoning and severe soft-tissue infections.
Medium-term (10 to 20 sessions): collagen makes; new wound-bed vessels start to form. Skin-surface oxygen on the wound bed often rises 50 to 100% over baseline by session 20.
Long-term (30 to 40 sessions): new vessel networks form in tissue that used to be starved of blood. The Hopf 2005 review of HBOT and vessel growth found that vessel density keeps rising through 40 sessions, then plateaus.
The 40-session protocol matches the angiogenesis plateau. Going past 40 sessions adds cost and oxygen-toxicity risk without much additional vascular gain.
Standard schedule: 5 days per week for 8 weeks
The dominant clinical schedule is 5 days per week (Monday through Friday) for 8 weeks. Weekend gaps allow recovery from pulmonary oxygen-toxicity exposure.
Some indications call for twice-daily ("BID") sessions in the first week. Necrotizing soft-tissue infections and crush injuries are the main BID indications. These are emergencies, not chronic-wound use cases.
For chronic indications — diabetic foot, radiation injury, stubborn bone infection — once-daily Monday through Friday is standard. The total dose targets the new-vessel plateau. See the osteomyelitis evidence atlas for the full study-by-study evidence breakdown.
Some clinics offer 3-day-per-week scheduling for off-label uses. The total session count is the same; the elapsed time stretches from 8 weeks to 13 weeks. There is no published evidence comparing daily vs 3x/week scheduling for therapeutic equivalence.
What "40 sessions" actually means at a hospital
A practical breakdown. A 40-session protocol at a hospital wound-care center looks like this.
Sessions 1 to 5 (week 1): patient acclimation, ear-equalization training, baseline transcutaneous oxygen measurement. Some patients drop out here due to ear pain or claustrophobia.
Sessions 6 to 20 (weeks 2 to 4): wound bed begins to show capillary growth. Granulation tissue appears in previously stalled ulcers. This is where most clinical observers start to see change.
Sessions 21 to 35 (weeks 5 to 7): mature vascularization develops. Wound closure progresses. Transcutaneous oxygen often doubles from baseline.
Sessions 36 to 40 (week 8): protocol completion. Re-measurement of transcutaneous oxygen. Decision to extend, stop, or refer for surgical closure.
Patients who do not show wound-bed improvement by session 20 are unlikely to benefit from continued treatment. The UHMS Indications Manual recommends a 20-session re-evaluation point.
Variants: 20, 60, 80, and beyond
Not every indication uses 40 sessions. We will cover the major variants.
For 20-session protocols, acute conditions like carbon monoxide poisoning use 1 to 3 sessions total. Necrotizing infections often complete in 10 to 20 sessions, where the biology is acute-phase rather than angiogenic.
For 60-session anti-aging protocols, the Aviv Clinics protocol runs 60 sessions at 2.0 ATA over 12 weeks. The rationale comes from Hadanny 2020 suggesting telomere lengthening at higher session counts.
We covered the gap between Aviv's protocol research and its marketing in our Aviv evidence-vs-marketing analysis. The 60-session protocol is consistent with the cited research, but the marketing language overstates what the data support.
For 80-session protocols, some wellness clinics offer 80+ sessions for combinations of off-label indications. There is no peer-reviewed evidence supporting session counts above 60 for chronic indications.
For maintenance and re-dosing, some clinics offer monthly sessions after completing a 40-session protocol. The clinical evidence for maintenance HBOT is essentially absent.
Why 40 is not "the magic number"
A common misconception. The 40-session figure is the right number for the indications that have been studied at that dose. It is not a universal therapeutic constant.
The original Marx and Faglia protocols happened to use 38 to 40 sessions because that is what fit a typical 8-week treatment window. Subsequent trials replicated the schedule, embedding 40 in the literature.
If the original trials had run 35 sessions and shown the same result, 35 would now be the standard. The number reflects how clinical research locks in once a treatment becomes routine — it does not reflect a discovered biological constant.
That said, 40 sessions does land near the angiogenesis plateau that most subsequent research has confirmed. The number is at least consistent with the underlying biology, even if it was not derived from dose-response work.
Cost implications
The 40-session count has direct financial consequences. We will lay out the math.
At a hospital wound-care center billing Medicare, a 40-session protocol costs Medicare approximately $25,000 to $30,000 (CMS HBOT fee schedule). Patient out-of-pocket is the standard Part B copay (20% after deductible).
At an independent hard-shell clinic billing private-pay at $400 per session, a 40-session protocol costs $16,000 out of pocket. Wellness clinics at $80 to $100 per session cost $3,200 to $4,000 for 40 sessions.
The Aviv Clinics 60-session protocol is priced around $50,000 (Aviv-published figures). That is a separate financial commitment from a routine 40-session clinical protocol.
The cost stack is the reason patients should verify their indication and the supporting evidence before signing on. A 40-session commitment is substantial whether paid by insurance or out of pocket.
How to read a clinic's recommendation
When a clinic recommends a specific session count, ask three questions.
What indication are they treating? Find that indication in the UHMS Indications Manual or in CMS LCD L33718. If the indication is FDA-approved, the session count should match published protocols (usually 30 to 40).
What evidence supports the session count? For FDA-approved indications, the evidence base is the original trials.
For off-label uses, ask which trials support the protocol. If the clinic cites "clinical experience" without published trials, treat that as marketing language.
What happens at the re-evaluation point? A reasonable clinic plans a 20-session re-evaluation. If the wound bed (or the off-label outcome measure) shows no change at 20, the clinic should be honest about whether to continue.
For more on judging clinic quality, see our chamber-verification guide and our UHMS accreditation explainer.
Pediatric and special-population protocols
The 40-session adult protocol does not transfer directly to pediatric or special populations.
Pediatric HBOT often uses shorter protocols. A 2018 review summarized common protocols at 20 to 40 sessions at 2.0 ATA. Children tolerate the chamber in a different way, and the conditions are not adult chronic wounds.
Patients with significant pulmonary disease (COPD, prior chest radiation) often get truncated protocols. The cumulative oxygen-toxicity exposure of 40 sessions at 2.4 ATA may exceed safe limits. Clinicians may shift to 30 sessions at 2.0 ATA in these patients.
Patients on some chemo drugs (cisplatin, bleomycin, doxorubicin) face higher lung toxicity from HBOT. These are usually contraindications, not dose-tweaks. The UHMS list has details.
Comparison with other protocols globally
The 40-session standard is dominant in the US. International protocols vary.
European HBOT centers often use 30 to 35 sessions for the same indications. The European Committee for Hyperbaric Medicine put out 2017 guidelines summarizing the per-indication norms.
Israeli centers — mainly the Sagol Center — have tried longer protocols (60+ sessions) for brain-aging research. The 2020 Hadanny telomere paper used 60 sessions.
Russian and Eastern European HBOT used very different protocols, often at lower pressures (1.5 to 1.8 ATA) for longer total times. These predate the modern evidence-based Western standards.
There is no global consensus on optimal session count. The 40-session US standard is well-supported for diabetic foot ulcer and radiation injury but not necessarily for off-label uses.
Bottom line
Forty sessions came from the diabetic-foot and radiation-osteonecrosis trials of the 1980s and 1990s. The number matches the angiogenesis plateau in chronic-wound research and has become the de facto US standard.
For FDA-approved indications, 40 sessions over 8 weeks at 2.0 to 2.5 ATA is well-evidenced. For off-label uses, the same session count is often used without comparable evidence.
The Aviv 60-session anti-aging protocol is a separate regimen with separate (and weaker) evidence. Wellness 80-session protocols generally lack supporting research.
If a clinic suggests a session count far from 40, ask what evidence backs that count for your specific use case.
Related Reading
- HBOT session duration: why 60 and 90 minute protocols exist
- Mild HBOT vs medical HBOT: why 1.3 ATA is controversial
- Aviv Clinics: evidence vs marketing
- How to verify a clinic's chamber is medical-grade
- UHMS-accredited HBOT facilities: what certification means
Frequently asked questions
Why exactly 40 sessions and not 30 or 50?
The 40-session figure came from the Marx radiation-osteonecrosis protocol and the Faglia diabetic-foot trial, both of which used 38 to 40 sessions. Subsequent research happened to match the original schedule, embedding the number.
Can I stop early if I see improvement?
Discuss with your physician. The standard re-evaluation point is session 20. Wound-bed improvement at that mark predicts response; lack of improvement may justify stopping or changing approach.
Is 60 sessions better than 40?
For FDA-approved indications, no published evidence supports 60 over 40. For anti-aging or cognitive indications, the Sagol Center research uses 60. The evidence base is much weaker than for the 40-session wound-care indications.
Do I have to go 5 days a week?
The 5-day schedule comes from the original trials. Some clinics offer 3-day schedules that stretch the protocol over 13 weeks. There is no published evidence comparing daily vs 3x weekly for therapeutic equivalence.
What if I miss a session?
Single missed sessions do not appear to significantly affect outcomes. Frequent missed sessions or long gaps may reduce the cumulative effect. Most protocols permit make-up sessions on Saturdays if needed.
Medical disclaimer: This guide is informational and does not constitute medical advice. HBOT carries real risks including ear barotrauma, oxygen toxicity, and chamber fire. Discuss any HBOT plan with a physician trained in undersea and hyperbaric medicine before starting. The FDA has cleared HBOT for 13 specific indications; uses outside those indications are off-label and not supported by FDA evaluation.
-- The HBOT Finder Team